Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Legend Bio Cleared to Start US Trials of CD4 CAR-T Candidate

publication date: Dec 14, 2020

Nanjing Legend Biotech was cleared to start a US Phase I trial of LB1901, a CAR-T therapy targeting CD4. The trial will enroll patients with relapsed-refractory T-Cell lymphoma, Legend explained that CD4 is expressed in a majority of TCL subtypes, though TCL, a heterogeneous group of disorders, occurs in less than 15% of US non-Hodgkin lymphoma cases. The endpoints of the LB1901 trial will be safety and tolerability, along with a recommended dose for the Phase II trial. More details....

Stock Symbol: (NSDQ: LEGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.